CHRS Live signals | Maximize Profits with Getagraph.com

BUY 102261 min ago

@ $2.65

Issued: 14 Feb 2024 @ 13:49

Return: -26.51%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 0.62 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 15:10):

Stats
Today's Volume	1.90M
Average Volume	2.71M
Market Cap	221.04M
EPS	$0 ( 2024-03-13 )
Next earnings date	( $-0.0500 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.770
ATR14	$0.00600 (0.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-20	Erbez Georgia	Buy	54 000	Stock Option (Right to Buy)
2024-02-20	Erbez Georgia	Buy	0
2024-02-09	Wahlstrom Mats	Buy	99 988	Common Stock
2024-02-09	Wahlstrom Mats	Sell	99 988	Common Stock
2024-02-01	Wahlstrom Mats	Buy	44 991	Common Stock

INSIDER POWER
42.73
Last 94 transactions
Buy: 4 570 164 \| Sell: 1 886 237

Volume Correlation

Long: 0.13 (neutral)

Short: 0.82 (strong)

Signal:(57.242) Same movement expected

Coherus BioSciences Inc Correlation

10 Most Positive Correlations
STRA	0.91
AVID	0.906
KPTI	0.887
EGRX	0.884
PARA	0.883
PINC	0.877
COLM	0.873
MDWD	0.868
IVAC	0.866
KTCC	0.865

10 Most Negative Correlations
MORF	-0.905
RXDX	-0.901
WPRT	-0.891
IMGN	-0.882
RESN	-0.875
MDWT	-0.872
FLMN	-0.871
ACOR	-0.866
ACVA	-0.861
IDCC	-0.857

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Coherus BioSciences Inc Correlation - Currency/Commodity

-0.52
( weak negative )

-0.41
( neutral )

0.00
( neutral )

-0.04
( neutral )

Coherus BioSciences Inc Financials

Annual	2023
Revenue:	$257.24M
Gross Profit:	$94.46M (36.72 %)
EPS:	$-2.53

Q4	2023
Revenue:	$91.52M
Gross Profit:	$5.89M (6.44 %)
EPS:	$-0.710

Q3	2023
Revenue:	$74.57M
Gross Profit:	$41.87M (56.14 %)
EPS:	$-0.410

Q2	2023
Revenue:	$58.72M
Gross Profit:	$33.87M (57.68 %)
EPS:	$-0.490

Financial Reports:

No articles found.

Coherus BioSciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.